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Background: Neurological impairment following ischemic insults is a major problem for stroke survivors. Xenon (Xe) has favorable neuroprotective 
properties. We have previously developed a novel methodology for ultrasound-controlled Xe delivery using Xe-containing echogenic liposomes (ELIP), 
and demonstrated their neuroprotective effects. This study evaluates the efficacy of Xe-ELIP as a neuroprotectant over time after the onset of a 
stroke.
Method: Xe-ELIP were created by a freeze-under-pressure method. Male Sprague-Dawley rats (n=12) underwent right middle cerebral artery 
occlusion for 2 hours. In the treatment groups, Xe-ELIP were administrated through the ascending right common carotid artery at 10, 60 and 180 
minutes after reperfusion with ultrasound application (0.26 MPa) to trigger Xe release from the Xe-ELIP. Infarction size and behavioral outcomes 
were determined 3 days after intervention.
Results: The freeze-under-pressure method encapsulated 10 μl of Xe in 1 mg of ELIP. Xe-ELIP administration at 10 minutes, 1 hour and 3 hours 
after reperfusion reduced the infraction size by 80±5.1% to 74±2% and 51±2.3%, respectively. All behavioral tests mirrored neurological results with 
improvements.
Conclusion: This study demonstrates the capability of Xe-ELIP to provide neuroprotection when administered within 3 hours, most effectively 
within 1 hour, after ischemia-reperfusion. This provides a novel strategy for enhanced therapeutic gas delivery to cerebral ischemia-related injury.
